Boston buoyed by drug-coated stent data
This article was originally published in Clinica
Executive Summary
Boston Scientific's first large-scale clinical trial of its paclitaxel-eluting stent has shown the device to be effective in preventing the biological effects that lead to a re-blockage of the coronary arteries following angioplasty with stenting.